Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8085162 | 0.79 | PDE4B (0.45) | PDE4BDRD3 | |
| SCHEMBL4983085 | 0.74 | LMNA (0.39) | ALOX5GABRA1CNR2GABRB2CYP3A4 | |
| SCHEMBL4986860 | 0.72 | ALOX5 (0.40) | PDE4BCYP19A1ALOX5GABRA1CNR2 | |
| SCHEMBL15347806 | 0.71 | GSK3B (0.45) | PDE4BCYP19A1TSHRPDE10A | |
| SCHEMBL295269 | 0.68 | CNR2 (0.46) | CNR2DRD3TSHR | |
| SCHEMBL17644543 | 0.68 | LRRK2 (0.57) | — | |
| SCHEMBL1633511 | 0.68 | DRD3 (0.36) | PDE4BCNR2DRD3 | |
| SCHEMBL3120324 | 0.68 | NPC1 (0.36) | PDE4BCNR2DRD3 | |
| SCHEMBL20537247 | 0.67 | LRRK2 (0.54) | — | |
| SCHEMBL20537313 | 0.66 | LRRK2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | PDE4B 891/4885CYP19A1 839/4885ALOX5 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.